Novo Nordisk A/S (NYSE:NVO) Shares Sold by Euro Pacific Asset Management LLC

Euro Pacific Asset Management LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,210 shares of the company’s stock after selling 2,152 shares during the period. Novo Nordisk A/S comprises 2.0% of Euro Pacific Asset Management LLC’s investment portfolio, making the stock its 23rd biggest position. Euro Pacific Asset Management LLC’s holdings in Novo Nordisk A/S were worth $11,144,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Orion Capital Management LLC purchased a new position in Novo Nordisk A/S during the first quarter worth $26,000. Gilliland Jeter Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. Finally, Halpern Financial Inc. lifted its position in shares of Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $101.74 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The firm has a market capitalization of $456.56 billion, a PE ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. The business has a 50-day moving average of $118.58 and a two-hundred day moving average of $129.58.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.